Immune Monitoring of Mycophenolate Mofetil Activity in Healthy Volunteers Using <i>Ex Vivo</i> T Cell Function Assays

• Main Authors: Aliede E. in 't Veld (Author), Manon A. A. Jansen (Author), Marieke L. de Kam (Author), Yalҫin Yavuz (Author), Dirk Jan A. R. Moes (Author), Kathalijne A. Oudhoff (Author), Mariette I. E. van Poelgeest (Author), Jacobus Burggraaf (Author), Matthijs Moerland (Author)
• Format: Book
• Published: MDPI AG, 2023-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Mycophenolate mofetil (MMF) is part of the standard immunosuppressive treatment after transplantation and usually given as "one-dose-fits-all" together with a calcineurin inhibitor (CNI). Although drug concentrations are frequently monitored, there is still a group of patients who experience side effects related to excessive or insufficient immune suppression. We therefore aimed to identify biomarkers that reflect the overall immune status of the patient and might support individualized dosing. We previously studied immune biomarkers for CNIs and aimed to investigate whether these are also suitable to monitor MMF activity. Healthy volunteers received a single dose of MMF or placebo, after which IMPDH enzymatic activity, T cell proliferation, and cytokine production were measured and compared to MPA (MMF's active metabolite) concentration in three different matrices (plasma, peripheral blood mononuclear cells, and T cells). MPA concentrations in T cells exceeded those in PBMCs, but all intracellular concentrations correlated strongly with plasma concentrations. At clinically relevant MPA concentrations, IL-2 and IFN-γ production was mildly suppressed, while MPA T cell proliferation was strongly inhibited. Based on these data, it is expected that monitoring of T cell proliferation in MMF-treated transplantation patients may be a valid strategy to avoid excessive immune suppression.

Item Description

10.3390/pharmaceutics15061635
1999-4923